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To describe the epidemiology and risk factors for cardiovascular disease (CVD) in survivors of adolescent and young adult (AYA) cancer.
Methods
We identified a retrospective cohort of 2-year survivors of AYA cancer who were diagnosed between the ages of 15 to 39 years (1998 to 2009) at Kaiser Permanente Southern California. A comparison group without cancer was selected and matched 10:1 to cancer survivors on the basis of age, sex, Kaiser Permanente Southern California membership, and calendar year. Patients were followed through December 31, 2012, for coronary artery disease, heart failure, and stroke. Timedependent Poisson regression was used to evaluate the effect that cancer survivorship had on the risk of developing CVD, adjusted for cardiovascular risk factors (CVRFs; ie, diabetes, hypertension, and dyslipidemia), ethnicity, smoking, and overweight/obesity. Among cancer survivors, mortality risk by CVD status was examined using Cox regression.
Results
A total of 5,673 2-year survivors of AYA cancer and 57,617 comparison patients were included, representing 24,839 and 239,073 person-years of follow-up, respectively. Overall, cancer survivors had more than two-fold risk of developing CVD (adjusted incidence rate ratio, 2.37; 95% CI, 1.93 to 2.93) when compared with patients without cancer; survivors of leukemia and breast cancer were at the highest risk (adjusted incidence rate ratio, 4.23; 95% CI, 1.73 to 10.31; and 3.63; 95% CI, 2.41 to 5.47, respectively) of developing CVD. Having any of the CVRFs increased the risk of CVD in cancer survivors. Cancer survivors who developed CVD had an 11-fold increased overall mortality risk (hazard ratio, 10.9; 95% CI, 8.1 to 14.8) when compared with survivors without CVD.
INTRODUCTION
Cardiovascular diseases (CVDs) are among the most debilitating late effects experienced by cancer survivors 1 and have emerged as a leading cause of nonrelapse-related mortality in this population.
2,3 Therefore, prevention, early detection, and intervention for cardiovascular late effects are critical for prolonging life and maintaining quality of life of cancer survivors.
Although considerable effort has been made to characterize long-term CVD outcomes in survivors of childhood cancer, [3] [4] [5] [6] few studies have adequately addressed CVD risk among survivors of cancers diagnosed after childhood. This is particularly the case for survivors of adolescent and young adult (AYA) cancer. 7 It has been recognized that the data from childhood cancer survivors may not be readily extrapolated to survivors of AYA cancer because the magnitude of late effects of cancer and its treatment may vary by age. 8 The relative risk increase for CVD among cancer survivors will also vary depending on the background rate of the disease in the general population.
To date, studies describing cardiovascular outcomes in AYA cancer have been limited to survivors of Hodgkin lymphoma (HL) and testicular cancer. 9, 10 Data on survivors of other cancer types are sparse. A few European studies have included all survivors of AYA cancers through population record linkage. [11] [12] [13] However, epidemiology of CVD among cancer survivors in the United States may be different from European countries given the differences in the health care environment and prevalence of risk factors, ethnic group, and genetic makeup. Here, we evaluated long-term CVD outcomes up to 12 years after cancer diagnosis of a retrospective cohort of approximately 6,000 2-year survivors of AYA cancer who were members of Kaiser Permanente Southern California (KPSC)-a large integrated health care system-with an established 5-and 10-year retention rate of 77% and 63%, respectively. 14 
METHODS

Study Setting and Study Population
KPSC is an integrated managed care organization that provides comprehensive health services to its members-more than 1% of the US population (3.6 million ethnically and socioeconomically diverse patients) who are broadly representative of the Southern Californian population.
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KPSC members who met the following eligibility criteria were included in the cohort of survivors of AYA cancer: diagnosed with invasive cancer at age 15 to 39 years, diagnosed at KPSC between 1998 and 2009, survived for at least 2 years (index date) after cancer diagnosis, remained a KPSC member at the index date, and retained at least 1 year of KPSC membership before the index date. Of those who met the inclusion criteria, survivors of AYA cancer diagnosed with another primary cancer before the index date were excluded. We identified cancer survivors using KPSC's SEER-affiliated cancer registry, which contains data on all patients who were diagnosed and/or treated for a new cancer at KPSC. Quality of the cancer registry data is assured by the SEER standard and is audited by SEER staff on a regular basis. 16 A cohort of KPSC members without a history of cancer was included for comparison. Patients without cancer were matched 10:1 to each individual survivor of AYA cancer by age (yearly), sex, and calendar year of the index date. The comparison patients without cancer for each cancer survivor were identified from those who were KPSC members in the year of the corresponding cancer diagnosis for that cancer survivor, survived and remained a KSPC member at the index date or later (ie, 2 years after), and retained at least 1 year of KSPC membership before the index date. This study excluded cancer survivors and the comparison patients without cancer diagnosed with one or more of the CVD outcomes of interest before the index date. All study patients were followed until the onset of CVD, end of 2012, death, or termination of KPSC membership, whichever came first. This study was approved by KPSC's Institutional Review Board.
Data Collection on Health Outcomes of Interest and Other Covariates
All data for this study were collected using KPSC's electronic health records. Record linkage across KPSC's clinical databases was performed using the unique member identifier for each study patient. The CVD outcomes of interest in this study included coronary artery disease, congestive heart failure (CHF), and stroke. The diagnosis of these CVD outcomes was captured using the International Classification of Diseases 9th and 10th revisions diagnosis codes (ICD9 and ICD10) and Current Procedural Terminology-4 procedure codes (Appendix Table A1 , online only). We required at least two outpatient diagnoses made on separate days, or one inpatient diagnosis, or CVD as the primary cause of death to define the presence of the condition.
Covariates of interest in this study included demographic characteristics; cancer characteristics; clinical CVD risk factors (CVRFs), namely diabetes, hypertension, and dyslipidemia; and lifestyle risk factors, such as smoking and overweight/obesity. Information on demographic characteristics was collected from KPSC's membership files; information on cancer characteristics was collected from KPSC's cancer registry. The diagnosis of diabetes was captured using the diabetes case identification algorithm developed by KPSC's case management system, which included the combination of ICD9 code, laboratory test results, and prescription medications. The diagnosis of hypertension and dyslipidemia was ascertained using a combination of ICD9 codes and the prescription of antihypertensive or lipid-lowering medications. History of smoking (ever or never smoking) and overweight/obesity at or before the index date was ascertained using ICD9 diagnosis codes and KPSC's internal social history and vital sign tables, respectively.
17 Information on death was collected using multiple data sources: KPSC's hospital, emergency room, and membership records; outside claims processing system; California state death records; and US Social Security death records.
Statistical Analysis
The distribution of demographic characteristics, cancer characteristics, and CVRFs was calculated among cancer survivors and the comparison patients. For all the analyses described in this section, we performed an overall analysis for all cancer types combined and a stratified analysis for selected cancer types (ie, breast, lymphoma, leukemia, melanoma, and thyroid cancer). The individual cancer types were selected as the sample size permitted for multivariable model fitting. The incidence rate of developing CVD was calculated by taking the number of new events divided by the person-time at risk. The crude and the adjusted incidence rate ratio (IRR) associated with being a cancer survivor compared with those without cancer was estimated using bivariate and multivariable Poisson regression adjusting for age, sex (except for breast cancer), and ethnicity (non-Hispanic white, non-Hispanic black, Hispanic, and Asian). In separate models, diabetes (yes/no), hypertension (yes/no), and dyslipidemia (yes/no), or smoking (yes/no) and overweight/obesity (yes/no) were also included to evaluate the impact of adjusting for these potential confounders. Diabetes, hypertension, and dyslipidemia were adjusted in a time-dependent manner.
The cumulative incidence of CVD was also calculated using methods accounting for competing risk. Differences in cumulative incidence of CVD between cancer survivors and those without cancer were tested using the Gray test. 18 Cumulative incidence curves over the follow-up period were generated for a visual inspection.
Multivariable, time-dependent Poisson regression was performed to evaluate the effect of having dyslipidemia, hypertension, and diabetes on risk of developing CVD outcomes within cancer survivors. Because of strong collinearity between the CVRFs in this analysis, separate models were built, each including one CVRF as a predictor, in addition to age, sex, ethnicity, cancer stage at diagnosis, smoking, and overweight/obesity. To examine if cancer survivors were at increased risk of developing each CVRF compared with those without cancer, separate multivariable Poisson regressions with dyslipidemia, hypertension, and diabetes being the outcomes were performed, adjusting for the same potential confounders.
Among cancer survivors, the risk of dying associated with having a CVD diagnosis was evaluated using a time-dependent Cox model to account for the time-varying nature of CVD and CVRF status. Bivariate analyses and multivariable analyses were both conducted adjusting for age, sex, ethnicity, CVRFs, smoking, and overweight/obesity. All analyses in this study were performed with SAS Version 9.3; Cary, North Carolina.
RESULTS
A total of 8,314 AYAs were diagnosed with invasive cancer between the ages of 15 and 39 years during 1998 to 2009 at KPSC. Of these, 7,474 survived at least 2 years and were eligible for this study. After applying the exclusion criteria, 5,673 survivors of AYA cancer and 57,617 patients without cancer were included in the analyses (Fig 1) . Table 1 presents the demographic and clinical characteristics of the study patients. Mean age at index date was 33.4 years for survivors of AYA cancer, and 35% were male. Both the cancer survivors and the comparison patients without cancer had substantial KPSC membership before the index date (mean, 7 to 8 years).
CVD Incidence and IRR Among Survivors of AYA Cancer
A total of 24,839 and 239,073 person-years at risk were observed among survivors of AYA cancer and comparison patients for the CVD incidence estimation, respectively ( Table 2 ). The mean years of follow-up was 4.4 (SD, 3.4, or 6.4 years after cancer diagnosis) and 4.1 (SD, 3.4) after index date for these two groups, respectively. Of the five cancer types examined separately, IRR was significantly elevated among all cancer types except for thyroid cancer. Adjusted IRR estimate was highest in leukemia survivors (IRR, 4.23) and lowest in survivors of lymphoma (IRR, 2.79) and melanoma (IRR, 2.94). Cancer survivors with CVD were slightly more likely to have CHF (34% v 28% of all CVD in cancer survivors v those without cancer; P = .21; data not shown), whereas the patients without cancer with CVD were more likely to have coronary artery disease (29% v 45%, P , .01). The proportions of patients with CVD with stroke were similar between the groups (42% v 40%, P = .63).
Cumulative Incidence Curves for CVD Accounting for Competing Risks
A steady increase in CVD cumulative incidence was observed immediately after index date among both survivors of AYA cancer and the comparison patients without cancer (Fig 2) . On the basis of visual inspection, there was no apparent change in the slope of the cumulative incidence during the study observation period for all cancer types combined; the same was true for survivors of breast, lymphoma, and melanoma cancer. For leukemia survivors, a slightly steeper slope was observed within approximately 1.5 years after index date (or 3 years after cancer diagnosis; Fig 2) . The Effect of CVRFs on Risk of CVD Among Survivors of AYA Cancer The development of CVRFs significantly increased the risk of CVD among survivors of AYA cancer. Of the three CVRFs examined, having diabetes or hypertension generally imposed a greater risk for CVD than dyslipidemia: adjusted IRR, 3.18 (95% CI, 1.85 to 5.46), 3.67 (95% CI, 2.38 to 5.67), and 1.79 (95% CI, 1.10 to 2.92) for diabetes, hypertension, and dyslipidemia, respectively ( Table 3 ). The associations between CVRFs and CVD, however, seemed to vary by cancer type.
Risk of Developing CVRFs Among Survivors of AYA Cancer
The incidence rate for developing diabetes, hypertension, and dyslipidemia was 60.4, 145.8, and 138.3 per 1,000 person-years among cancer survivors and 42.7, 110.0, and 117.1 per 1,000 person-years among the comparison group without cancer, respectively. On average, survivors of AYA cancer were at increased risk for developing diabetes and dyslipidemia when compared with patients without cancer (Table 4) . These associations also seemed to vary by cancer type.
All-Cause Mortality Among Cancer Survivors With and Without CVD
In a bivariate time-dependent Cox model, survivors of AYA cancer who developed CVD had a 19-fold increased risk of dying compared with survivors of AYA cancer without CVD (hazard ratio, 18.9; 95% CI, 14.2 to 25.0; P , .01). After adjusting for demographics, cancer stage at diagnosis, the presences of the CVRFs, smoking, and obesity, cancer survivors with CVD remained at an 11-fold risk of dying compared with those without CVD (adjusted hazard ratio, 10.9; 95% CI, 8.1 to 14.8; P , .01). Survival at 5 and 10 years after index date (ie, 7 and 12 years after cancer diagnosis) was 0.67 and 0.55 in survivors who developed CVD and 0.92 and 0.90 in survivors without CVD, respectively. .51
Abbreviations: AYA, adolescent and young adult; CVD, cardiovascular disease; CVRF, cardiovascular disease risk factors (ie, hypertension, diabetes, and dyslipidemia); IRR, incidence rate ratio; SD, standard deviation. *Incidence rate per 1,000 person-years. †Sex was not adjusted in the breast cancer analysis.
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DISCUSSION
In this study we observed an overall two-fold CVD risk increase for survivors of AYA cancer when compared with demographically matched patients without cancer. Furthermore, survivors of AYA cancer who developed CVD were had a 10-fold increased risk of dying compared with survivors without CVD. Given the marked increased mortality among survivors who develop CVD, there is an opportunity for improving patient outcomes by improving primary and secondary CVD prevention. These data suggest that prevention needs to be emphasized across the full spectrum of cardiovascular disease development, starting from risk factors, and potentially with tailored CVD/CVRF screening schedules for survivors of AYA cancer.
Among survivors of AYA cancer, the presence of one or more of the CVRFs increased the risk of developing CVD compared with survivors without any CVRFs. Cancer survivors also had an increased risk of developing one or more CVRFs. However, despite this, accounting for the differences of CVRFs did not fully explain the increased CVD risk seen in these survivors. The remaining risk increase may be attributable to cardiotoxic cancer treatments or a shared pathogenic mechanism between cancer and CVD (ie, oxidative stress, genetic traits). These data suggest the need for strategies other than CVRF prevention for CVD risk reduction in these cancer survivors, including the evaluation of novel cancer treatment regimens that minimize cardiovascular toxicity.
Although studies on long-term health outcomes among survivors of AYA cancers are sparse, data related to cardiovascular late effects are emerging from several European studies. A study by Rugbjerg et al 11 reported a 30% risk increase for CVD-related hospital discharge among 1-year or longer survivors of AYA cancer in Denmark. The greatest risk increase was found for Hodgkin lymphoma (relative risk, 12.2; 95% CI, 9.9 to 15.0), whereas the smallest risk increase was found for thyroid cancer (relative risk, 1.2; 95% CI 1.0 to 1.4). A study by Kero et al 12 examined 5-year cancer survivors diagnosed between age 20 and 34 years in Finland and reported increased risk of CVD-related hospitalizations compared with siblings. When stratified by cancer type, significantly elevated risk of CVD hospitalization was observed among survivors of lymphomas, CNS tumor, and testicular cancer but not of breast cancer or thyroid cancer. It should be noted that a wide spectrum of CVD-related hospital diagnoses were included in these studies, including asymptomatic conditions and hypertension. In Kero et al, 12 the greatest risk increase among cancer survivors was found for cardiomyopathy. This was not the case, however, in Rugbjerg et al.
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In general, the magnitude of CVD risk increase among survivors of AYA cancer compared with their peers without cancer seems to be lower than that observed in survivors of childhood cancer. Investigators from the Childhood Cancer Survivor Study found a six-fold risk of congestive heart failure and a five-fold risk of myocardial infarction among survivors of childhood cancer compared with siblings without cancer. 19 However, it is important to note that all study participants were . 5-year cancer survivors, thus had longer follow-up than in the current study, and included self-reported CVD; these differences may explain in part the differences in magnitude of risk between the Childhood Cancer Survivor Study and the current study. In studies that evaluated long-term CVD outcomes in both survivors of AYA and childhood cancer under the same system and using the same approach, a higher risk of CVD increase was observed in survivors of childhood cancers than that in survivors of AYA cancers 12 (including our own work at KPSC 20 ). This phenomenon may reflect the possibility that the effect of cancer treatment on a developing versus mature organ may vary substantially, or that the background CVD rate in the adult population is simply higher, or both.
There are several potential limitations that should be considered when interpreting our results. First, it is possible that cancer survivors are under more vigilant medical surveillance, including individuals who have disease relapse or are receiving maintenance therapy (eg, lymphoblastic lymphoma and leukemia). Moreover, a subset of breast cancer survivors may still be receiving ovarian suppression and/or hormonal therapy more than 2 years from diagnosis, potentially altering their CVD risk profile and hence provider screening practices. Recognizing the potential for detection bias, we limited our case definition of CVD to clinically overt disease (myocardial infarction, CHF, and stroke) and excluded diagnoses (ie, arrhythmia, valvular disease, asymptomatic atherosclerosis) that may only be detected during screening in an asymptomatic individual. We did not find an increased risk of CVD or CVRFs across all cancer types, suggesting that detection bias likely did not account for all the differences Abbreviations: AYA, adolescent and young adult; CVRF, cardiovascular disease risk factors; IRR, incidence rate ratio (reference group was noncancer comparison patients). *Adjusted for age, sex, ethnicity, smoking, and overweight/obesity. Sex was not adjusted in the breast cancer analysis. observed between cancer survivors and the comparison cohort without cancer. Second, our ascertainment of smoking and overweight/obesity was in part based on ICD9 coding. Thus, these risk factors might be undercoded. However, given the minimal change in IRR estimates in the adjusted and unadjusted analysis, it is unlikely that the increased risk observed would be fully explained by the undercaptured smoking or overweight/obesity. Last, we did not evaluate individual cancer types other than breast cancer, hematologic cancer, melanoma, and thyroid cancer because of the small number of CVD events observed in the other cancer types. Despite these limitations, our study has several strengths. Our cancer survivors and population comparisons came from the same community-based practice and had similar health care coverage, which minimizes bias due to differential health care access. Another unique contribution of our study was the ability to collect longitudinal data on CVRFs and to examine the role of CVRFs in the development of CVD among survivors of AYA cancer. This is attributed to the unique integrated care model of KPSC, in which primary care, subspecialty care, and any inpatient and outpatient encounter can be adequately captured. Furthermore, cancer treatments have evolved over the past several decades, especially with regard to their impact on delayed health outcomes.
21 Survivors of AYA cancer in this cohort were diagnosed and treated in a fairly recent era (ie, 1998 to 2009); thus, our study provided an analysis of CVD outcomes most relevant to contemporary patients with AYA cancer.
Late effects associated with cancer and its treatment pose significant risks to the health and quality of life of cancer survivors. Understanding these long-term morbidities and mortality bears a critical role in survivorship planning and clinical management. In general, our data suggested survivors of AYA cancers are at a more than doubled risk of developing CVD compared with the general population. Additional research is needed to understand the impact of AYA cancer treatment and the role of lifestyle risk/ preventive factors in these cancer survivors.
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